“Provectus is a great fit for irlabs and we are excited to help the Company increase its visibility and engagement with retail and institutional investors," said
About Provectus
Provectus’s medical science platform includes clinical development programs in oncology, dermatology, and ophthalmology; proof-of-concept in vivo development programs in oncology, hematology, full-thickness cutaneous wound healing, and canine cancers; and in vitro discovery programs in infectious diseases, tissue regeneration and repair, and proprietary targets.
Information about the Company’s clinical trials can be found at the
FORWARD-LOOKING STATEMENTS: The information in this press release may include “forward-looking statements,” within the meaning of
The safety and efficacy of the agents and/or uses under investigation have not been established. There is no guarantee that the agents will receive health authority approval or become commercially available in any country for the uses being investigated or that such agents as products will achieve any particular revenue levels.
Due to the risks, uncertainties, and assumptions inherent in forward-looking statements, readers should not place undue reliance on these forward-looking statements. The forward-looking statements contained in this press release are made as of the date hereof or as of the date specifically specified herein, and Provectus undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except in accordance with applicable securities laws. The forward-looking statements are expressly qualified by this cautionary statement.
Risks, uncertainties, and assumptions include those discussed in the Company’s filings with the
- The Company’s Annual Report on Form 10-K for the period ended
December 31, 2022 , and - Provectus’s Quarterly Report on Form 10-Q for the period ended
September 30, 2023 .
#####
Contact:
Chief Financial Officer
Phone: (866) 594-5999
Source:
2024 GlobeNewswire, Inc., source